Upper Respiratory Tract Infection Associated with Anti-HER2 Antibody Blockade for HER2-Positive Breast Cancer: A Bayesian Disproportionality Analysis Using Data From the FDA Adverse Event Reporting System
T-DM1 treatment has a higher possibility for URTI development with higher severity, followed by pertuzumab, trastuzumab, and T-DXd. Patients receiving anti-HER2 antibody treatment, particularly T-DM1, should receive special attention regarding URTI incidence and severity.
Authors
- Xi Chen (ORCID: https://orcid.org/0000-0001-8473-7920)
- Yuan Zhang (ORCID: https://orcid.org/0000-0001-5236-2626)
- Yang� Yang (ORCID: https://orcid.org/0000-0003-1222-1209)
- Jie Zhao (ORCID: https://orcid.org/0009-0008-5457-8226)
Institutions
- Zhejiang Chinese Medical University (CN)
- Palestine Polytechnic University (PS)
- Shanghai Cancer Institute (CN)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1016/j.clinthera.2025.09.015
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05